Solventum Corporation

Solventum Corporation

SOLV

$89.35

Updated: 05/11/2026, 08:31:46

Market Cap
$15.21B
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Country
US

No historical data available

Company Profile

Solventum Corporation, established in 2023 and headquartered in Saint Paul, Minnesota, operates as a healthcare entity dedicated to pioneering, producing, and commercializing diverse solutions that address critical needs for both customers and patients. The company's business activities are organized into four principal segments. The Medsurg division furnishes various products and services, including sophisticated wound care items, intravenous (I.V.) site management tools, sterilization assurance systems, temperature regulation devices, surgical instruments, stethoscopes, and medical electrodes. Its Dental Solutions segment provides a comprehensive range of dental and orthodontic offerings, such as brackets, clear aligners, restorative filling materials, and bonding agents. The Health Information Systems division concentrates on advanced software platforms, covering functionalities like computer-assisted physician documentation, direct billing and coding automation, classification frameworks, voice recognition capabilities, and data visualization tools. Finally, the Purification and Filtration segment supplies an array of purification and filtration technologies, including various filters, purifiers, cartridges, and specialized membranes.

USD
NYSE
CEO: Bryan C. Hanson
Employees: 20,584
https://www.solventum.com
Asset Summaries
Latest generated summaries for SOLV

No summaries found.

Detailed business
Evidence-backed facts extracted from the latest official annual filing.
SOLV-10-k-fy2025.html2.9 MBtext/htmlENFiled 27/02/2026Period ended 31/12/2025

Business monitoring

Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.

Evidence-backed · 43 KPI observations

Revenue

N/A

FY — · Reported

Net income

$1.6B

FY 2025 · Reported

Gross margin

N/A

FY — · Reported

Free cash flow

$-0.0B

FY 2025 · Calculated

R&D intensity

N/A

FY — · Reported

Share repurchases

N/A

FY — · Reported

Earnings and cash generation
USD billions, directly sourced from inline XBRL; free cash flow is operating cash flow less capex.
Profitability and reinvestment
Margins and R&D as a percentage of revenue.
Geographic footprint
What the filing identifies, separated by location role so partner manufacturing is not presented as Apple-owned factories.
1 named headquarters
0 manufacturing countries
0 individually named factories

Map layer

Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.

No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosure
Named headquarters Manufacturing partner country

Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.

How the business makes money

Spin-off from 3M

Solventum spun off from 3M; commercial relationships with 3M remain significant

98%
Source evidence
“Following the Spin-Off, Solventum’s commercial relationships with 3M remain significant, which could adversely affect Solventum’s business”

Company overview

Leading global healthcare company with 70+ year history; solutions present along patient's journey through prevention, diagnosis, treatment, and recovery

98%
Source evidence
“Solventum Corporation ("Solventum," "we," "our," "us," or the "Company"), is a leading global healthcare company developing, manufacturing, and commercializing a broad portfolio of solutions that leverages deep material science, data science, and digital capabilities”

Company overview

Solventum is a leading global healthcare company developing, manufacturing, and commercializing a broad portfolio of solutions that leverages deep material science, data science, and digital capabilities

98%
Source evidence
“Solventum is a leading global healthcare company developing, manufacturing, and commercializing a broad portfolio of solutions that leverages deep material science, data science, and digital capabilities to address critical customer and patient needs.”

Dental Solutions segment

Dental Solutions: 16.2% of 2025 total sales; dental and orthodontic products spanning the "life of the tooth"

99%
Source evidence
“Dental Solutions (16.2% of 2025 total sales) is a provider of a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents”

MedSurg segment

MedSurg: 57.9% of 2025 total sales; wound care, infection prevention, surgical supplies, medical OEM

99%
Source evidence
“MedSurg (57.9% of 2025 total sales) is a provider of solutions including negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies”

Health Information Systems segment

Health Information Systems: 16.3% of 2025 total sales; healthcare software for revenue cycle and clinician productivity

99%
Source evidence
“Health Information Systems (16.3% of 2025 total sales) provides healthcare systems with software solutions – including computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms”

Reportable business segments

Three reportable segments: MedSurg, Dental Solutions, and Health Information Systems

98%
Source evidence
“Solventum manages its operations in three reportable business segments: MedSurg, Dental Solutions, and Health Information Systems.”

Customer base

Diverse customer base from multidisciplinary hospitals to local clinics/practices with long-tenured relationships

94%
Source evidence
“We serve a diverse customer base, ranging from multidisciplinary hospitals to local clinics/practices.”

Continued supply agreements with 3M

Sales from non-health care supply agreements conveyed from 3M at Spin-Off and new supply agreements with 3M commenced at Spin-Off

90%
Source evidence
“non-health care related supply agreements that conveyed from 3M to the Company at Spin-Off and sales from new supply agreements with 3M that commenced at Spin-Off”

FY2025 segment net sales

FY2025 total net sales $8,325M: MedSurg $4,817M; IP&SS $2,934M; AWC $1,883M; HIS $1,360M; Dental $1,349M; P&F $497M; All Other $302M

97%
Source evidence
“Advanced Wound Care$1,883 $1,835 2.6 %0.5 %2.1 %0.1 %2.0 % Infection Prevention and Surgical Solutions2,934 2,802 4.7 0.5 4.2 (0.4)4.5 MedSurg4,817 4,637 3.9 0.6 3.3 (0.2)3.5”

Operations and dependencies

Foreign currency exchange risk

Material portion of revenues outside the U.S. creates FX exposure, especially to USD strengthening

95%
Source evidence
“Because Solventum’s financial statements are denominated in U.S. dollars and a material percentage of its revenues are derived from outside the U.S., Solventum’s results of operations and its ability to realize projected growth rates in sales and earnings could be adversely affected by volatility in foreign currency exchange rates”

3M sole source of raw materials

3M is sole source of supply for raw materials used in certain products

98%
Source evidence
“3M is the sole source of supply for raw materials used in certain of our products and our business will be harmed if 3M does not satisfy our requirements.”

Employee base

~20,000 employees (~10,000 US, ~2,000 Germany, ~4,000 production); 40% >10 years tenure; no US unionized facilities

96%
Source evidence
“Our employee base consists of approximately 20,000 employees, with approximately 40% having more than 10 years of tenure. We have approximately 10,000 employees in the United States and approximately 2,000 in Germany.”

Positioning and strategy

Acquisition of Acera Surgical

Acquired Acera Surgical (regenerative wound care bioscience) on Dec 23, 2025 for $696M net cash plus $125M sales-based milestone payment

99%
Source evidence
“on December 23, 2025, Solventum acquired Acera Surgical ("Acera"), a privately held bioscience company focused on developing and commercializing fully engineered materials for regenerative wound care, for cash consideration of $696 million, net of cash acquired, plus a future payment of $125 million dependent on the acquired business achieving a sales-based milestone”

Acera Surgical acquisition (2025)

In 2025, acquired Acera Surgical, a privately held bioscience company

95%
Source evidence
“In 2025, the Company acquired Acera Surgical ("Acera"), a privately held bioscience company.”

Acera acquired December 2025

Sales from Acera acquired in December 2025 included in acquisition-related component of sales change

90%
Source evidence
“Acquisitions include sales from Acera that was acquired in December 2025”

Differentiated capabilities

Strong customer relationships, broad portfolio of brands, differentiated technology, and manufacturing expertise

90%
Source evidence
“Our business possesses strong customer relationships, a broad, wide-ranging, and well-known portfolio of brands, differentiated technology, and manufacturing expertise.”

Dental Solutions competitors

Dental competitors: Dentsply Sirona, Envista, Straumann, Ivoclar (dental only), Align Technology (orthodontic only)

97%
Source evidence
“Principal multinational competitors within the oral care market include Dentsply Sirona, Envista, and Straumann”

Health Information Systems competitors

HCIT competitors: Optum, Microsoft (Nuance), Epic, Oracle (Cerner), Waystar, Athena plus start-ups; fragmented value-based care market

97%
Source evidence
“Principal competitors include Optum, Microsoft (Nuance), Epic, Oracle (Cerner), Waystar, Athena, and a host of start-up technologies actively working to disrupt the areas of revenue cycle management and clinician productivity.”

MedSurg competitors

Advanced wound care: Smith & Nephew, Medaxis, Mölnlycke, Coloplast, Convatec; infection prevention/surgical: Becton Dickinson, Hartmann, ICU Medical, Medline, Cardinal Health, Fortive, Steris, MDF Instruments, BSN

97%
Source evidence
“the advanced wound care market is highly competitive, particularly in the United States and Europe, with our principal competitors including Smith & Nephew, Medaxis, Mölnlycke, Coloplast, and Convatec.”

Aging demographics and chronic conditions drive demand

Aging population, chronic conditions prevalence, and rising middle class driving demand for improved access to quality care

95%
Source evidence
“An aging population, the prevalence and incidence rates of chronic conditions, and a rising middle class are driving the demand for improved access to quality care.”

Shift from hospital to lower-cost care sites

Care shifting from hospitals to ambulatory surgery centers, wound care clinics, retail pharmacies, and the home; Solventum solutions enable care across acute to home settings

93%
Source evidence
“Alternative care sites, such as ambulatory surgery centers, wound care clinics, retail pharmacies, and the home, are more affordable and accessible to patients.”

Administrative waste in US healthcare spending

Of $5.3 trillion annual U.S. healthcare spending, ~25% is administrative costs; Solventum solutions target workflow optimization

92%
Source evidence
“Of the $5.3 trillion in annual U.S. healthcare spending, an estimated 25% represents administrative costs that do not contribute to health outcomes”

Increasing demand for personalized care

Personalized care demand includes customized orthodontic aligner treatments and at-home wound care follow-up

90%
Source evidence
“This spans several areas of healthcare, including customized orthodontic aligner treatments, and follow-up wound care at home.”

Sale of Purification & Filtration business to Thermo Fisher

Closed sale of P&F business to Thermo Fisher Scientific for $4.0B cash on September 2, 2025

99%
Source evidence
“on September 2, 2025, Solventum announced the close of its sale of the Purification & Filtration business ("P&F") to Thermo Fisher Scientific Inc. for $4.0 billion in cash before customary adjustments”

Sale of Purification and Filtration business to Thermo Fisher

Completed sale of Purification and Filtration business to Thermo Fisher Scientific on September 1, 2025 for approximately $4 billion cash; drinking water filtration business excluded from scope

98%
Source evidence
“On September 1, 2025, Solventum completed the sale of the Business to the Buyer in accordance with the terms of the Agreement. The cash consideration paid to Solventum at closing was approximately $4 billion.”

Purification and Filtration divestiture (2025)

In 2025, sold Purification and Filtration business to Thermo Fischer Scientific Inc.

95%
Source evidence
“Also in 2025, the Company sold its Purification and Filtration business to Thermo Fischer Scientific Inc.”

Divestiture of Purification and Filtration business

Purification and Filtration business divested; proceeds used to repay debt

95%
Source evidence
“the subsequent repayment of debt with proceeds from the divestiture of the Purification and Filtration business”

Digital technology, data, and AI-driven care delivery

Growing demand for digital tools including AI-enabled capabilities and data analytics in care delivery

92%
Source evidence
“the use of data, analytics, and artificial intelligence (AI) to support informed health decisions, the need for digital tools in the healthcare industry has grown over time.”

R&D organization scale

R&D team of approximately 2,000 employees; segment-level full product development life cycle plus cross-segment shared technologies

95%
Source evidence
“Our R&D team consists of approximately 2,000 employees, including research scientists, chemical engineers, data scientists, software engineers, and product developers.”

Intellectual property protection

IP protection is a strategic priority; no single IP asset material; customer understanding, technology expertise, manufacturing know-how deemed critical

93%
Source evidence
“Development and protection of our proprietary technologies through IP rights is a strategic priority for our business.”

Expected Spin-Off benefits

Standalone benefits: capital allocation, focus, agility, capital access, equity currency, talent

90%
Source evidence
“(4) greater access to capital through the creation of a distinct and compelling investment profile appealing to a different long-term investor base from 3M; (5) independent equity currency, enabling Solventum to use its own industry-focused stock to consummate future acquisitions”

Risks, financing, and outlook

Outstanding indebtedness ~$5 billion

~$5 billion outstanding indebtedness as of Dec 31, 2025

98%
Source evidence
“as of December 31, 2025, Solventum had approximately $5 billion of outstanding indebtedness”

Separation-related debt constrains cash flow

Debt incurred in connection with separation from 3M adversely affects profitability and could restrict investing, M&A, and capital returns

95%
Source evidence
“the debt obligations incurred by Solventum in connection with the separation will adversely affect its profitability and could affect its ability to use its cash flow for investing in the business, strategic transactions, including mergers and acquisitions, and returning capital.”

Credit ratings affect cost of capital and customer relationships

Credit rating downgrade to below investment grade could raise funding costs and cause customer losses

93%
Source evidence
“a reduction in Solventum’s credit rating to below investment-grade could cause certain customers to reduce or cease to do business with Solventum, which would adversely impact its financial performance”

No dividends intended

No dividends currently intended; returns rely on stock appreciation

90%
Source evidence
“Because Solventum does not currently intend to pay any dividends on its common stock, holders of its common stock must rely on stock appreciation for any return on their investment.”

Divestiture-related sales headwind from 3M India retained businesses

Divestiture impacts include lost P&F sales, businesses retained by 3M India at Spin-Off, and other immaterial divested businesses

88%
Source evidence
“Divestiture impacts include lost sales from the Company's Purification and Filtration business that was sold in September 2025, certain health care businesses retained by 3M India in connection with the Spin-Off”

Strictly regulated medical products industry

Products regulated in most markets; non-compliance could trigger recalls, fines, license revocation, consent decrees or criminal prosecution

95%
Source evidence
“These actions may have a negative impact on Solventum’s capital expenditures, earnings and competitive position.”

EHS regulatory compliance

Subject to evolving EHS laws across jurisdictions covering emissions, GHG, hazardous materials, permitting and licensing across all segments

92%
Source evidence
“These affect a significant portion of our activities globally across each of our segments and product lines and require compliance related to, among other things: (a) occupational health, safety, and well-being; (b) the protection of the environment; (c) emissions and discharges to air and water; (d) greenhouse gas management and climate change”

Sustainability and climate reporting mandates

Expanding sustainability disclosure mandates (EU CSRD, California climate reporting) and product-focused laws raise compliance cost

90%
Source evidence
“including the European Union’s Corporate Sustainability Reporting Directive (CSRD), legislation in California requiring reporting of greenhouse gas emissions and climate risk and similar regulatory requirements in other jurisdictions”

PFAS exposure and product dependency with 3M indemnification limits

3M ceased supplying PFAS products end of 2025; Solventum responsible for PFAS liabilities after 2025 indemnification window

97%
Source evidence
“The potential options available to Solventum following 2025 (after which sales by Solventum of products containing or enabled by PFAS will no longer be subject to indemnification from 3M), regarding PFAS in products will involve risks, which risks may be material”

PFAS-related liabilities

Potential PFAS-related liabilities

97%
Source evidence
“Solventum may face potential liabilities related to PFAS, which could adversely impact Solventum’s results.”

Competitive pressure and AI-driven disruption, particularly in HIS business

Highly competitive healthcare markets with pricing pressure and AI-driven disruption risk, notably for the Health Information Systems (HIS) business

96%
Source evidence
“(vi) the emergence of new AI-enabled competitors and business model disruption, particularly for our HIS business”

Tax-free spin-off conditionality

Two-year Tax Matters Agreement restrictions to preserve tax-free spin-off treatment

95%
Source evidence
“the Tax Matters Agreement restricts Solventum, for the two-year period following the distribution, except in specific circumstances, from”

Tax liabilities if Spin-Off fails to qualify

Risk of significant tax liabilities if Spin-Off fails to qualify as tax-free

95%
Source evidence
“If the Spin-Off, together with certain related transactions, were to fail to qualify as a transaction that is generally tax-free for U.S. federal income tax purposes, Solventum and its shareholders could be subject to significant tax liabilities.”

Loss of 3M brand benefits post-spin

Solventum may be negatively impacted by loss of benefits of 3M's brand recognition and reputation after the Spin-Off

95%
Source evidence
“Following the separation, Solventum is operating under its own brand, and accordingly may be negatively impacted due to the loss of benefits conferred by 3M's brand recognition and reputation.”

Highly competitive, disruptive healthcare markets

Highly competitive markets and healthcare consolidation risk

93%
Source evidence
“Solventum operates in highly competitive markets, competition may increase in the future and the healthcare industry may be disrupted, necessitating that Solventum lower prices or resulting in a loss of market share.”

Interest rate exposure including variable rate debt

Exposed to interest rate changes via variable rate debt and counterparty effects

92%
Source evidence
“Solventum is exposed to changes in interest rates, including through variable rate debt and due to the fact that increases in interest rates may adversely affect the financial condition of Solventum’s counterparties”

Input availability vulnerability

Vulnerability to materials, energy, production capacity and labor availability

90%
Source evidence
“Solventum’s future results are subject to vulnerability with respect to materials and availability of purchased components, compounds, raw materials, energy, production capacity and labor.”

Reimbursement and cost containment demand risk

Reimbursement/cost-containment pressure on demand and pricing

90%
Source evidence
“Changes in reimbursement practices of third-party payers or other cost containment measures or worsening economic conditions could affect the demand for Solventum’s products and the prices at which they are sold.”

Capital markets access risk

May be unable to access capital and credit markets on favorable terms, or at all, in adverse conditions

90%
Source evidence
“Solventum could need access to the capital markets to supplement its existing funds and cash generated from operations to satisfy its needs for working capital, to meet capital expenditure and debt service requirements”

Currency and interest rate exposure

FX and interest rate risk

90%
Source evidence
“Changes in foreign currency exchange rates or interest rates could adversely affect Solventum.”

Climate change physical and transition risks

Climate change poses physical supply chain risks and transition costs including carbon taxes and shifting customer preferences

90%
Source evidence
“Failure to provide climate-friendly products or demonstrate greenhouse gas reductions could result in loss of market share.”

Cybersecurity risk

Cyberattacks and data breaches could disrupt operations

90%
Source evidence
“Security and data breaches, cyberattacks and other cybersecurity incidents involving Solventum’s information technology systems and infrastructure could disrupt or interfere with Solventum’s operations.”

Restructuring program and integration risk

Restructuring and acquisition integration risk

88%
Source evidence
“Solventum's restructuring program may not be successful.”

AI deployment risk

AI and emerging technology adoption risk

85%
Source evidence
“The deployment of artificial intelligence or other emerging technologies in Solventum's products and services, or a failure to adapt its products and services, could affect future results.”

Material exposure graph

MedSurg solutions
Revenue Exposure

MedSurg is the largest segment at 57.9% of 2025 total sales, driven by wound care, infection prevention, and surgical supplies demand.

Relevance 95·Dependency 90·Confidence 98
Source evidence
“MedSurg (57.9% of 2025 total sales) is a provider of solutions including negative pressure wound therapy”
3M
Supplier Dependency

3M is the sole source of supply for raw materials used in certain Solventum products; failure of 3M to supply would harm the business.

Relevance 95·Dependency 85·Confidence 97
Source evidence
“3M is the sole source of supply for raw materials used in certain of our products and our business will be harmed if 3M does not satisfy our requirements.”
Hospitals and clinics/practices
Customer Exposure

All three segments serve healthcare providers from multidisciplinary hospitals to local clinics/practices; long-tenured relationships drive retention.

Relevance 85·Dependency 80·Confidence 94
Source evidence
“We serve a diverse customer base, ranging from multidisciplinary hospitals to local clinics/practices.”
MedSurg segment
Revenue Exposure

MedSurg is the largest segment with FY2025 sales of $4,817M (58% of total), growing 3.9% reported / 3.5% organic

Relevance 85·Dependency 75·Confidence 97
Source evidence
“MedSurg4,817 4,637 3.9 0.6 3.3 (0.2)3.5”
Medical product regulations
Legal Exposure

Products are regulated in most served markets; compliance failures can trigger recalls, fines, license revocation and criminal prosecution.

Relevance 85·Dependency 70·Confidence 95
Source evidence
“Solventum commits a significant amount of resources to maintain compliance with these regulations and standards”
Changing demographics
Demand Driver

Aging population and chronic conditions drive demand for Solventum's healthcare solutions

Relevance 85·Dependency 60·Confidence 93
Source evidence
“An aging population, the prevalence and incidence rates of chronic conditions, and a rising middle class are driving the demand for improved access to quality care.”
3M
Legal Exposure

3M indemnifies Solventum for certain PFAS liabilities only through 2025 product sales; after 2025 Solventum bears PFAS-related regulatory and litigation exposure and lost 3M PFAS supply.

Relevance 85·Dependency 60·Confidence 95
Source evidence
“3M ceased supplying Solventum with PFAS-related products or components at the end of 2025.”
PFAS liabilities
Legal Exposure

Potential PFAS-related liabilities could adversely impact results of operations.

Relevance 85·Dependency 50·Confidence 90
Source evidence
“Solventum may face potential liabilities related to PFAS, which could adversely impact Solventum’s results.”
Healthcare providers and payers
Demand Driver

Reimbursement constraints push providers/payers to reduce avoidable administrative costs, driving demand for Solventum workflow optimization solutions

Relevance 80·Dependency 65·Confidence 90
Source evidence
“As healthcare providers and payers face increasing reimbursement constraints and evolving payment models, the need to reduce avoidable administrative costs has become more acute.”
3M
Revenue Exposure

Ongoing commercial relationships with 3M remain significant post-Spin-Off and could adversely affect the business and stock price.

Relevance 80·Dependency 60·Confidence 90
Source evidence
“Following the Spin-Off, Solventum’s commercial relationships with 3M remain significant, which could adversely affect Solventum’s business”
PFAS restrictions
Regulatory Exposure

Accelerating global PFAS restrictions and litigation create material risk for products containing or enabled by PFAS after the 3M indemnification window ends.

Relevance 80·Dependency 50·Confidence 92
Source evidence
“There have been accelerating regulatory and legislative activities concerning PFAS globally, including increasingly strict restrictions on various uses of PFAS in products, as well as increased litigation relating to PFAS”
Purification and Filtration business
Revenue Exposure

P&F divested September 2025 to Thermo Fisher for ~$4B; segment sales fell 29.9% to $497M, driving -3.0% 'other' sales impact

Relevance 80·Dependency 0·Confidence 95
Source evidence
“Purification and Filtration497 709 (29.9)1.1 (31.0)(36.5)5.5”
AI and digital care delivery
Demand Driver

Shift toward digitally enabled, AI-supported care drives demand for Solventum's integrated digital solutions

Relevance 78·Dependency 55·Confidence 90
Source evidence
“Whether it is interactions with patients through a digital interface or the use of data, analytics, and artificial intelligence (AI) to support informed health decisions, the need for digital tools in the healthcare industry has grown over time.”
Separation debt service
Cost Driver

Debt incurred in separation adversely affects profitability and constrains cash deployment; cost of servicing debt is a risk to market opportunities

Relevance 75·Dependency 70·Confidence 90
Source evidence
“the cost to service the debt we incurred in connection with the separation”
Health Information Systems software
Revenue Exposure

HIS contributed 16.3% of 2025 total sales via healthcare software for revenue cycle and clinician productivity.

Relevance 75·Dependency 65·Confidence 97
Source evidence
“Health Information Systems (16.3% of 2025 total sales) provides healthcare systems with software solutions”
Healthcare regulation
Regulatory Exposure

Solventum operates in a strictly regulated industry; compliance is costly and failures may result in significant penalties.

Relevance 75·Dependency 55·Confidence 85
Source evidence
“Solventum operates in a strictly regulated industry, and compliance with laws and regulations applicable to the commercialization of Solventum’s products is costly and failure to comply may result in significant penalties.”
AI-enabled competition
Competitive Exposure

AI-enabled competitors and disruptive technologies pose business model disruption risk, particularly for the HIS business, affecting demand and pricing.

Relevance 75·Dependency 45·Confidence 93
Source evidence
“the emergence of new AI-enabled competitors and business model disruption, particularly for our HIS business”
Lower-cost care sites (ASCs, wound clinics, retail pharmacies, home)
Demand Driver

Shift of care from hospitals to lower-cost alternative sites drives demand for Solventum solutions across care settings

Relevance 72·Dependency 50·Confidence 88
Source evidence
“Alternative care sites, such as ambulatory surgery centers, wound care clinics, retail pharmacies, and the home, are more affordable and accessible to patients.”
Interest rates
Cost Driver

With ~$5 billion of debt, changes in interest rates could adversely affect Solventum; credit rating changes could raise funding costs.

Relevance 70·Dependency 65·Confidence 90
Source evidence
“Changes in foreign currency exchange rates or interest rates could adversely affect Solventum.”
Dental Solutions products
Revenue Exposure

Dental Solutions contributed 16.2% of 2025 total sales via dental and orthodontic products.

Relevance 70·Dependency 60·Confidence 97
Source evidence
“Dental Solutions (16.2% of 2025 total sales) is a provider of a comprehensive suite of dental and orthodontic products”
Third-party payers
Demand Driver

Changes in third-party payer reimbursement practices and cost containment measures could affect demand and pricing for products.

Relevance 70·Dependency 60·Confidence 85
Source evidence
“Changes in reimbursement practices of third-party payers or other cost containment measures or worsening economic conditions could affect the demand for Solventum’s products and the prices at which they are sold.”
US Dollar
Currency Exposure

USD-denominated statements with material non-US revenues mean USD strength could reduce reported sales and earnings growth.

Relevance 70·Dependency 55·Confidence 93
Source evidence
“particularly if the value of the U.S. dollar strengthens significantly against foreign currencies”
Smith & Nephew
Competitive Exposure

Smith & Nephew is a principal competitor in the highly competitive advanced wound care market, particularly in the US and Europe.

Relevance 70·Dependency 55·Confidence 95
Source evidence
“the advanced wound care market is highly competitive, particularly in the United States and Europe, with our principal competitors including Smith & Nephew, Medaxis, Mölnlycke, Coloplast, and Convatec.”
Tax Matters Agreement
Tax Exposure

Tax-free treatment of the spin-off depends on compliance with Tax Matters Agreement restrictions on equity transactions and business changes for two years post-distribution.

Relevance 70·Dependency 55·Confidence 90
Source evidence
“To preserve the tax-free treatment of the distribution and certain related transactions, and in addition to Solventum’s indemnity obligation described below, the Tax Matters Agreement restricts Solventum, for the two-year period following the distribution”
3M
Revenue Exposure

Spin-Off from 3M: loss of brand benefits, 3M India retained businesses create divestiture sales headwinds, and ongoing supply agreements with 3M contribute sales

Relevance 70·Dependency 55·Confidence 88
Source evidence
“certain health care businesses retained by 3M India in connection with the Spin-Off, as well as impacts from other immaterial divested businesses”
Environmental, Health and Safety laws and regulations
Regulatory Exposure

EHS permitting, licensing, emissions, and hazardous materials rules affect a significant portion of activities globally across each segment.

Relevance 65·Dependency 60·Confidence 90
Source evidence
“These affect a significant portion of our activities globally across each of our segments and product lines and require compliance”
Foreign currency exchange
Currency Exposure

Changes in foreign currency exchange rates could adversely affect results; repatriation of earnings could trigger withholding taxes raising the effective tax rate.

Relevance 60·Dependency 50·Confidence 85
Source evidence
“requiring Solventum to repatriate earnings to the U.S., causing withholding taxes to be applied, which in turn could increase Solventum’s effective tax rate; and”
EU Corporate Sustainability Reporting Directive
Regulatory Exposure

CSRD and similar climate/sustainability reporting mandates increase compliance burdens and costs for Solventum and its supply chain.

Relevance 60·Dependency 35·Confidence 88
Source evidence
“Solventum and companies in its supply chain may experience increased compliance burdens and costs to meet the regulatory obligations”
Dentsply Sirona
Competitive Exposure

Dentsply Sirona is a principal multinational competitor in dental and orthodontic solutions.

Relevance 55·Dependency 45·Confidence 95
Source evidence
“Principal multinational competitors within the oral care market include Dentsply Sirona, Envista, and Straumann”
Climate policy and carbon costs
Cost Driver

Carbon taxes, cap-and-trade, and sterilization/disposal climate-related costs could raise Solventum's cost structure and shift customer demand.

Relevance 55·Dependency 30·Confidence 85
Source evidence
“imposing climate-related costs associated with product sterilization, disposal, or recycling; and/or imposing an economic cost on carbon such as through carbon taxes or cap-and-trade systems”
Full company information
Latest profile, trading, valuation, and identifier data stored for SOLV.
Share price
$89.35
Market cap
$15.21B
Exchange
NYSE
Currency
USD
CEO
Bryan C. Hanson
Employees
20,584
IPO date
01/04/2024
Beta
0.747
Last dividend
$0.00
Day range
$88.57 – $90.60
52-week range
$62.38 – $94.16
1-day performance
5.42%
1-year performance
43.24%
Current drawdown (1Y)
-5.11%
CIK
0001964738
CUSIP
83444M101
ISIN
US83444M1018
Created
07/12/2025, 14:20:12
Last update
05/11/2026, 08:31:46

Track Solventum Corporation with an AI analyst

See which prediction-market events move SOLV, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to SOLV from your Railway `news_articles` table.

Earnings Growth & Price Strength Make Solventum (SOLV) a Stock to Watch

Zacks Investment Research • STOCK • 09/06/2026, 12:31:14

Solventum Trends for 2026: AI Coding, Tariffs, and Margins

Zacks Investment Research • STOCK • 08/06/2026, 16:35:14

SOLV Energy Announces Full Exercise and Closing of Underwriters' Option to Purchase Additional Shares of Class A Common Stock

GlobeNewsWire • STOCK • 04/06/2026, 19:18:00

Solventum Corporation (SOLV) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 03/06/2026, 14:02:06

SOLV Energy Announces Pricing of Upsized Public Offering of Class A Common Stock

GlobeNewsWire • STOCK • 28/05/2026, 22:35:00

SOLV Energy, Inc. (MWH) Q1 2026 Earnings Call Transcript

Seeking Alpha • STOCK • 15/05/2026, 17:50:44

SOLV or HQY: Which Is the Better Value Stock Right Now?

Zacks Investment Research • STOCK • 15/05/2026, 14:40:51

Solventum Corporation (SOLV) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 13/05/2026, 17:40:48

SOLV Energy Q1 Earnings Call Highlights

MarketBeat • STOCK • 12/05/2026, 13:10:53

Solventum Stock Down Despite Q1 Earnings & Revenues Beat Estimates

Zacks Investment Research • STOCK • 06/05/2026, 15:10:16

Solventum (SOLV) Recently Broke Out Above the 20-Day Moving Average

Zacks Investment Research • STOCK • 06/05/2026, 12:35:37

Solventum (SOLV) Recently Broke Out Above the 50-Day Moving Average

Zacks Investment Research • STOCK • 06/05/2026, 12:30:39